The final, formatted version of the article will be published soon.
REVIEW article
Front. Aging Neurosci.
Sec. Alzheimer's Disease and Related Dementias
Volume 16 - 2024 |
doi: 10.3389/fnagi.2024.1429211
This article is part of the Research Topic A comprehensive look at biomarkers in neurodegenerative diseases: from early diagnosis to treatment response assessment View all 8 articles
Alzheimer's Disease: A Review on the Current Trends of the Effective Diagnosis and Therapeutics
Provisionally accepted- 1 College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
- 2 Faculty of Medicine, Bioscience, and Nursing, Mahsa University, Selangor, Malaysia
The most prevalent cause of dementia is Alzheimer's disease. Cognitive decline and accelerating memory loss characterise it. Alzheimer's disease advances sequentially, starting with preclinical stages, followed by mild cognitive and/or behavioural impairment, and ultimately leading to Alzheimer's disease dementia. In recent years, healthcare providers have been advised to make an earlier diagnosis of Alzheimer's, prior to individuals developing Alzheimer's disease dementia. Regrettably, the identification of early-stage Alzheimer's disease in clinical settings can be arduous due to the tendency of patients and healthcare providers to disregard symptoms as typical signs of aging. Therefore, accurate and prompt diagnosis of Alzheimer's disease is essential in order to facilitate the development of disease-modifying and secondary preventive therapies prior to the onset of symptoms. There has been a notable shift in the goal of the diagnosis process, transitioning from merely confirming the presence of symptomatic AD to recognising the illness in its early, asymptomatic phases. Understanding the evolution of diseasemodifying therapies and putting effective diagnostic and therapeutic management into practice requires an understanding of this concept. The outcomes of this study will enhance in-depth knowledge of the current status of Alzheimer disease's diagnosis and treatment, justifying the necessity for the quest for potential novel biomarkers that can contribute to determining the stage of the disease, particularly in its earliest stages. Interestingly, latest clinical trial status on pharmacological agents, the nonpharmacological treatments such as behaviour modification, exercise, and cognitive training as well as alternative approach on phytochemicals as neuroprotective agents have been covered in detailed.
Keywords: Alzheimer's disease, AD, Dementia, diagnosis, Treatment, Clinical Trial
Received: 07 May 2024; Accepted: 25 Jul 2024.
Copyright: © 2024 Abdul Manap, Almadodi, Sultana, Sebastian, Kavani, Lyenouq and Shankar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Aimi Syamima Abdul Manap, College of Veterinary Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.